» Articles » PMID: 28954459

Clinical Significance of Periurethral Calcification According to the Location in Men With Lower Urinary Tract Symptoms and a Small Prostate Volume

Overview
Journal Int Neurourol J
Date 2017 Sep 29
PMID 28954459
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To assess the impact of periurethral calcification (PUC) according to its location on uroflowmetric parameters and urinary symptoms in patients with small prostate volume (PV).

Methods: Records were obtained from a prospectively maintained database of first-visit men with lower urinary tract symptoms (LUTS). Patients whose PV was >30 mL were excluded to elucidate more clearly the impact of PUC on LUTS. A total of 539 patients were enrolled in the study. The prostatic urethra was examined by transrectal ultrasonography for PUC, and the location of PUC was divided into 3 areas (proximal, mid, and distal).

Results: The characteristics according to the location of PUC were compared using a 1-way analysis of variance test. The Total International Prostate Symptom Score (IPSS), postmicturition symptoms, and overactive bladder symptom score (OABSS) differed significantly among the groups. In the propensity score matching analysis, the proximal- and distal-PUC groups did not have a significantly different urinary flow rate or symptom score when compared to their matched control groups. However, the mid-PUC group had significantly worse urinary symptoms than its matched control group (total IPSS [P=0.001], voiding symptoms [P=0.002], storage symptoms [P=0.041], and OABSS [P=0.015]). The peak urinary flow rate was also lower in the mid-PUC group with borderline significance (P=0.082). On multivariate linear regression analysis, mid-PUC was independently associated with IPSS and OABSS (P=0.035 and P=0.011, respectively).

Conclusions: Only mid-PUC was associated with symptom severity in men with LUTS and a small PV. Our findings suggest that mid-PUC could be a potential causal factor of LUTS, and the midportion of the prostatic urethra might play a pivotal role in the process of micturition.

Citing Articles

Tamsulosin and Dutasteride Combination Therapy for Asian Men With Moderate-to-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review of Clinical Considerations That Influence the Prescription.

Yang F, Hashim R, Philippou J J Clin Med Res. 2024; 16(9):385-397.

PMID: 39346571 PMC: 11426169. DOI: 10.14740/jocmr5255.


Clinical significance of distally located periurethral calcification in patients with lower urinary tract symptoms of benign prostate hyperplasia.

Yu S, Lim D, Kim S Asian J Androl. 2022; 25(3):361-365.

PMID: 35946225 PMC: 10226498. DOI: 10.4103/aja202245.


The influence of prostatic calculi on lower urinary tract symptoms and sexual dysfunction: a narrative review.

Wang H, Ma M, Qin F, Yuan J Transl Androl Urol. 2021; 10(2):929-938.

PMID: 33718093 PMC: 7947430. DOI: 10.21037/tau-20-1046.


Resveratrol reduces inflammation-related Prostate Fibrosis.

Vicari E, Arancio A, Catania V, Vicari B, Sidoti G, Castiglione R Int J Med Sci. 2020; 17(13):1864-1870.

PMID: 32788865 PMC: 7415386. DOI: 10.7150/ijms.44443.


Predictors Of Postoperative Lower Urinary Tract Symptoms Improvements In Patient With Small-Volume Prostate And Bladder Outlet Obstruction.

Li X, Wu Y, Ke Z, Lin T, Chen S, Xue X Ther Clin Risk Manag. 2019; 15:1291-1304.

PMID: 31806981 PMC: 6844295. DOI: 10.2147/TCRM.S219331.

References
1.
Huckabay C, Nitti V . Diagnosis and treatment of primary bladder neck obstruction in men. Curr Urol Rep. 2005; 6(4):271-5. DOI: 10.1007/s11934-005-0020-7. View

2.
Kim K, Ahn B, Lim S, Han W, Kim J, Rha K . Indenter study: associations between prostate elasticity and lower urinary tract symptoms. Urology. 2014; 83(3):544-8. DOI: 10.1016/j.urology.2013.10.061. View

3.
Kaplan S, Lee J, Meehan A, Kusek J . Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 2011; 185(4):1369-73. PMC: 3677556. DOI: 10.1016/j.juro.2010.11.060. View

4.
Kaplan S, McConnell J, Roehrborn C, Meehan A, Lee M, Noble W . Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006; 175(1):217-20. DOI: 10.1016/S0022-5347(05)00041-8. View

5.
Rodriguez-Nieves J, Macoska J . Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol. 2013; 10(9):546-50. PMC: 5625295. DOI: 10.1038/nrurol.2013.149. View